Omnicell, Inc. (NASDAQ:OMCL) EVP Jorge R. Taborga sold 19,796 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $83.86, for a total value of $1,660,092.56. Following the sale, the executive vice president now directly owns 36,156 shares in the company, valued at approximately $3,032,042.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Omnicell stock opened at $84.60 on Friday. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of 55.29, a price-to-earnings-growth ratio of 3.91 and a beta of 1.25. Omnicell, Inc. has a 1 year low of $41.59 and a 1 year high of $86.87.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 7th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.16. The firm had revenue of $211.75 million for the quarter, compared to analyst estimates of $215.41 million. Omnicell had a net margin of 4.79% and a return on equity of 9.31%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 earnings per share. Sell-side analysts predict that Omnicell, Inc. will post 1.83 earnings per share for the current year.
Several equities research analysts recently commented on the company. BidaskClub raised Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. ValuEngine raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Zacks Investment Research lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Monday, December 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $80.00 price target (up previously from $70.00) on shares of Omnicell in a research report on Thursday, December 6th. Finally, Dougherty & Co lifted their price target on shares of Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Omnicell presently has a consensus rating of “Buy” and an average target price of $76.56.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Preferred Stock
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.